These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 32556142

  • 1. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
    Casu C, Pettinato M, Liu A, Aghajan M, Lo Presti V, Lidonnici MR, Munoz KA, O'Hara E, Olivari V, Di Modica SM, Booten S, Guo S, Neil G, Miari R, Shapir N, Zafir-Lavie I, Domev H, Ferrari G, Sitara D, Nai A, Rivella S.
    Blood; 2020 Oct 22; 136(17):1968-1979. PubMed ID: 32556142
    [Abstract] [Full Text] [Related]

  • 2. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
    Schmidt PJ, Fitzgerald K, Butler JS, Fleming MD.
    Am J Hematol; 2021 Feb 01; 96(2):251-257. PubMed ID: 33180328
    [Abstract] [Full Text] [Related]

  • 3. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.
    Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, Watt A, Freier S, Monia BP, Rivella S.
    J Clin Invest; 2013 Apr 01; 123(4):1531-41. PubMed ID: 23524968
    [Abstract] [Full Text] [Related]

  • 4. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
    Schmidt PJ, Toudjarska I, Sendamarai AK, Racie T, Milstein S, Bettencourt BR, Hettinger J, Bumcrot D, Fleming MD.
    Blood; 2013 Feb 14; 121(7):1200-8. PubMed ID: 23223430
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
    Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, Camaschella C.
    Blood; 2012 May 24; 119(21):5021-9. PubMed ID: 22490684
    [Abstract] [Full Text] [Related]

  • 7. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
    Schmidt PJ, Liu K, Visner G, Fitzgerald K, Fishman S, Racie T, Hettinger JL, Butler JS, Fleming MD.
    Am J Hematol; 2018 Jun 24; 93(6):745-750. PubMed ID: 29498084
    [Abstract] [Full Text] [Related]

  • 8. Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6.
    Lee P, Hsu MH, Welser-Alves J, Peng H.
    Blood Cells Mol Dis; 2012 Mar 15; 48(3):173-8. PubMed ID: 22244935
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice.
    Wake M, Palin A, Belot A, Berger M, Lorgouilloux M, Bichon M, Papworth J, Bayliss L, Grimshaw B, Rynkiewicz N, Paterson J, Poindron A, Spearing E, Carter E, Hudson R, Campbell M, Petzer V, Besson-Fournier C, Latour C, Largounez A, Gourbeyre O, Fay A, Coppin H, Roth MP, Theurl I, Germaschewski V, Meynard D.
    Blood Adv; 2024 Apr 23; 8(8):1898-1907. PubMed ID: 38241484
    [Abstract] [Full Text] [Related]

  • 15. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
    Di Modica SM, Tanzi E, Olivari V, Lidonnici MR, Pettinato M, Pagani A, Tiboni F, Furiosi V, Silvestri L, Ferrari G, Rivella S, Nai A.
    Am J Hematol; 2022 Oct 23; 97(10):1324-1336. PubMed ID: 36071579
    [Abstract] [Full Text] [Related]

  • 16. A critical role for murine transferrin receptor 2 in erythropoiesis during iron restriction.
    Wallace DF, Secondes ES, Rishi G, Ostini L, McDonald CJ, Lane SW, Vu T, Hooper JD, Velasco G, Ramsay AJ, Lopez-Otin C, Subramaniam VN.
    Br J Haematol; 2015 Mar 23; 168(6):891-901. PubMed ID: 25403101
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease.
    Olivari V, Di Modica SM, Lidonnici MR, Aghajan M, Cordero-Sanchez C, Tanzi E, Pettinato M, Pagani A, Tiboni F, Silvestri L, Guo S, Ferrari G, Nai A.
    Kidney Int; 2023 Jul 23; 104(1):61-73. PubMed ID: 36990212
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.